Search

Abstract: Aim: The aim of this study was to determine the effect of local recurrence on overall survival in patients with intermediate high‐grade localized primary soft tissue sarcoma (STS) of extremity and abdominothoracic wall. Methods: This retrospective study identified 133 consecutive patients with intermediate high‐grade localized primary STS of extremity and abdominothoracic wall from January 2000 to July 2010. Survival curves were constructed by the Kaplan–Meier method and log‐rank test was used to assess statistical significance. Hazard ratios (HRs) were calculated based on multivariable Cox logistic regression method. Results: The 5‐year cumulative incidence of local recurrence was 26.0% with a median follow‐up of 68 months (range, 5–127 months). The univariate analysis showed that local recurrence was associated with decreased overall survival, with 5‐year overall survival of 80.5% and 53.6% in the no local recurrence patients and local recurrence patients, respectively (P = 0.001). The multivariate analysis demonstrated that local recurrence was a negative prognostic factor for overall survival (HR = 2.115, 95% confidence interval [CI] 1.036–4.319, P = 0.040). Radiotherapy significantly reduced local recurrence compared with surgery alone (HR = 0.387, 95% CI 0.180–0.877, P = 0.019), while larger tumor size (HR = 3.184, 95% CI 1.351–7.506 P = 0.008) was correlated with higher rate of local recurrence. Conclusion: Local recurrence in patients with intermediate high‐grade localized primary STS is associated with decreased overall survival. [ABSTRACT FROM AUTHOR]

This prospective study aimed at assessing the efficiency and safety of concurrent chemoradiotherapy ( CCRT) using paclitaxel ( PTX) plus oxaliplatin ( OHP) in unresectable locally advanced esophageal cancer patients. Between January 2006 and December 2010, 34 patients with unresectable locally advanced esophageal cancer were enrolled in this study. Radiotherapy was delivered with a daily fraction of 2.0 Gy to a total dose of 60 Gy over 6 weeks. Concurrent PTX (135 mg/m², d1) and OHP (130 mg/m², d1) were administered on Day 1 and Day 29 of radiotherapy. Of these patients, 76.5% completed the treatment course with a response rate of 73.5%, including eight (23.5%) patients with complete response and 17 (50.0%) patients with partial response. The median overall survival ( OS) time was 23.7 months (range: 4.0-65.5 months) with 1-, 3- and 5-year OS rates were 64.3%, 36.6% and 25.8%, respectively. The median progression-free survival ( PFS) time was 21.2 months with 1-, 3- and 5-year PFS rates were 63.8%, 30.9% and 20.4%, respectively, During the CCRT course, the main grade 3 or greater acute toxicities were leukopenia (38.2%), esophagitis (14.7%), and dysphagia (11.8%), with late toxicity being infrequent. Although this study did not meet its primary endpoint, the application of CCRT with PTX and OHP in unresectable locally advanced esophageal carcinoma yielded satisfactory clinical outcomes and manageable toxicities. [ABSTRACT FROM AUTHOR]